Ventseslav D.
- Country
- Bulgaria
- Department
- Internal Diseases Department
Research Overview
- A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
- Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of VE202 in Mild-to-Moderate Ulcerative Colitis Patients
- Comparative Efficacy, Safety, and Immunogenicity of Intravenous AVT16 Versus Vedolizumab in Adults with Moderate to Severe Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 37 of 203 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating various forms of ulcerative colitis, demonstrating expertise across the disease severity spectrum from mild to severe presentations.
- Mild-to-moderate ulcerative colitis treatment
- Left-sided ulcerative colitis interventions
- Moderate to severe active disease management
Particular focus on innovative therapeutic approaches for inflammatory bowel conditions.
Novel Therapeutic Applications
Expertise in evaluating advanced treatment modalities including biosimilar therapeutics and novel drug delivery systems for gastrointestinal disorders.
- Rectal solution therapies
- Biological treatment evaluation
- Alternative delivery mechanisms
Focused on developing targeted therapeutic solutions for gastrointestinal inflammation.
Clinical Efficacy Assessment
Specializes in evaluating treatment effectiveness through comprehensive clinical assessment and endoscopic response monitoring.
- Endoscopic evaluation
- Clinical remission assessment
- Comparative treatment analysis
Expertise in measuring therapeutic outcomes in inflammatory bowel conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.